Subtopic Deep Dive

Multidrug-Resistant Stenotrophomonas Infections
Research Guide

What is Multidrug-Resistant Stenotrophomonas Infections?

Multidrug-resistant Stenotrophomonas maltophilia infections are nosocomial infections caused by this intrinsically resistant Gram-negative bacterium, prevalent in immunocompromised patients and ICUs.

S. maltophilia shows increasing incidence in ventilated and neutropenic patients, with resistance driven by efflux pumps and low outer membrane permeability (Brooke, 2012; 1377 citations). Clinical outcomes involve bacteremia in ICU cohorts, often linked to prior carbapenem exposure. IDSA guidelines recommend trimethoprim-sulfamethoxazole or levofloxacin as first-line therapies (Tamma et al., 2021; 476 citations).

Curated Papers

Key Challenges

Why It Matters

MDR S. maltophilia infections surge in ICU patients on ventilators, contributing to high mortality in bacteremia cases (Brooke, 2012). Risk factors like neutropenia and carbapenem use necessitate stewardship to preserve options like colistin combinations (Chang et al., 2015). IDSA guidance highlights ceftazidime-avibactam and minocycline for targeted therapy in resistant strains (Tamma et al., 2021; Tamma et al., 2024). This impacts global antimicrobial management, with over 1377 citations underscoring its opportunistic threat (Brooke, 2012).

Key Research Challenges

Intrinsic Resistance Mechanisms

S. maltophilia exhibits low outer membrane permeability and efflux pumps conferring resistance to multiple classes (Livermore, 2002; 1426 citations). These mechanisms limit beta-lactam efficacy, as noted in comparisons to Pseudomonas aeruginosa (Poole, 2011; 918 citations).

Limited Treatment Options

Few agents like trimethoprim-sulfamethoxazole remain effective amid rising resistance (Tamma et al., 2021; 476 citations). ICU cohorts show poor outcomes with monotherapy, pushing colistin combinations (Chang et al., 2015; 406 citations).

Risk Factor Identification

Neutropenia and prior carbapenem exposure drive infections, complicating prophylaxis (Brooke, 2012). Epidemiological tracking lags behind Gram-negative resistance trends (Nordmann and Poirel, 2019; 670 citations).

Essential Papers

Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?

D. M. Livermore · 2002 · Clinical Infectious Diseases · 1.4K citations

Pseudomonas aeruginosa carries multiresistance plasmids less often than does Klebsiella pneumoniae, develops mutational resistance to cephalosporins less readily than Enterobacter species, and has ...

Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen

Joanna S. Brooke · 2012 · Clinical Microbiology Reviews · 1.4K citations

SUMMARY Stenotrophomonas maltophilia is an emerging multidrug-resistant global opportunistic pathogen. The increasing incidence of nosocomial and community-acquired S. maltophilia infections is of ...

Pseudomonas Aeruginosa: Resistance to the Max

Keith Poole · 2011 · Frontiers in Microbiology · 918 citations

Pseudomonas aeruginosa is intrinsically resistant to a variety of antimicrobials and can develop resistance during anti-pseudomonal chemotherapy both of which compromise treatment of infections cau...

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria

Patrice Nordmann, Laurent Poirel · 2019 · Clinical Infectious Diseases · 670 citations

Abstract Carbapenem resistance in gram-negative bacteria has caused a global epidemic that continues to grow. Although carbapenemase-producing Enterobacteriaceae have received the most attention be...

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections

Yohei Doi · 2019 · Clinical Infectious Diseases · 636 citations

Abstract Antimicrobial resistance has become one of the greatest threats to public health, with rising resistance to carbapenems being a particular concern due to the lack of effective and safe alt...

Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections

Pranita D. Tamma, Emily L. Heil, Julie Ann Justo et al. · 2024 · Clinical Infectious Diseases · 629 citations

Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections. This guidance document focuses...

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo et al. · 2023 · Clinical Infectious Diseases · 623 citations

Abstract Background The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses o...

Reading Guide

Foundational Papers

Start with Brooke (2012; 1377 citations) for pathogen overview and Livermore (2002; 1426 citations) for resistance mechanisms, as they establish S. maltophilia's global threat and comparisons to Pseudomonas.

Recent Advances

Study Tamma et al. (2024; 629 citations) and Tamma et al. (2021; 476 citations) for updated IDSA treatments; Chang et al. (2015; 406 citations) details therapeutic options.

Core Methods

Efflux pump inhibition, susceptibility testing per CLSI, and cohort risk analysis via logistic regression; IDSA grading of evidence quality.

How PapersFlow Helps You Research Multidrug-Resistant Stenotrophomonas Infections

Discover & Search

Research Agent uses searchPapers and exaSearch to find S. maltophilia literature, revealing 'Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen' by Brooke (2012; 1377 citations). citationGraph maps IDSA guidelines (Tamma et al., 2021) connections to resistance mechanisms. findSimilarPapers expands to Chang et al. (2015) on therapeutic options.

Analyze & Verify

Analysis Agent applies readPaperContent to extract resistance data from Livermore (2002), then verifyResponse with CoVe checks claims against Tamma et al. (2024). runPythonAnalysis processes ICU cohort stats via pandas for survival rates. GRADE grading scores IDSA evidence as high-quality for treatment recommendations.

Synthesize & Write

Synthesis Agent detects gaps in colistin combination trials, flagging contradictions between Brooke (2012) and recent IDSA updates. Writing Agent uses latexEditText for protocol drafts, latexSyncCitations for 10+ papers, and latexCompile for figures. exportMermaid generates resistance mechanism flowcharts.

Use Cases

"Analyze survival rates in MDR S. maltophilia bacteremia from ICU studies using Python."

Research Agent → searchPapers → Analysis Agent → readPaperContent (Chang 2015) → runPythonAnalysis (pandas aggregation of cohort data) → matplotlib survival plots.

"Draft LaTeX review on IDSA guidelines for S. maltophilia infections."

Synthesis Agent → gap detection → Writing Agent → latexEditText (add sections) → latexSyncCitations (Tamma 2021/2024) → latexCompile → PDF output.

"Find code for S. maltophilia resistance gene analysis from papers."

Research Agent → searchPapers → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on repo scripts for efflux pump simulations.

Automated Workflows

Deep Research workflow scans 50+ papers on S. maltophilia resistance via searchPapers → citationGraph → structured report with GRADE scores. DeepScan applies 7-step verification: readPaperContent (Brooke 2012) → CoVe → runPythonAnalysis on mechanisms. Theorizer generates hypotheses on colistin synergies from Tamma et al. (2021) and Chang et al. (2015).

Try Doxa for Multidrug-Resistant Stenotrophomonas Infections Research

Frequently Asked Questions

What defines multidrug-resistant Stenotrophomonas infections?

Infections by S. maltophilia, a Gram-negative opportunist with intrinsic resistance via efflux and low permeability, affecting ICU immunocompromised patients (Brooke, 2012).

What are key treatment methods?

IDSA prefers trimethoprim-sulfamethoxazole or levofloxacin; alternatives include minocycline or ceftazidime-avibactam for resistant cases (Tamma et al., 2021; Tamma et al., 2024).

What are seminal papers?

Brooke (2012; 1377 citations) on emergence; Livermore (2002; 1426 citations) on mechanisms; Tamma et al. (2021; 476 citations) on IDSA guidance.

What open problems exist?

Optimizing colistin combinations, predicting resistance from carbapenem exposure, and prospective trials for novel agents amid rising ICU incidence (Chang et al., 2015).